Novo Nordisk A/SNVONYSE
Loading
Income Before Tax Over TimeStrong
Percentile Rank93
3Y CAGR+22.0%
5Y CAGR+18.8%
Year-over-Year Change
Pre-tax earnings
3Y CAGR
+22.0%/yr
vs +9.7%/yr prior
5Y CAGR
+18.8%/yr
Recent acceleration
Acceleration
+12.3pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.4x
Strong expansion
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $125.53B | -1.3% |
| 2024 | $127.19B | +21.5% |
| 2023 | $104.67B | +51.6% |
| 2022 | $69.06B | +16.9% |
| 2021 | $59.08B | +11.2% |
| 2020 | $53.13B | +9.4% |
| 2019 | $48.55B | +2.0% |
| 2018 | $47.62B | -2.2% |
| 2017 | $48.68B | +1.8% |
| 2016 | $47.80B | - |